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Background: : Disability-free life expectancy (DFLE) inequalities by socioeconomic deprivation are widening,
alongside rising prevalence of multiple long-term conditions (MLTCs). We use longitudinal data to assess
whether MLTCs contribute to the widening DFLE inequalities by socioeconomic deprivation.
Methods: : The Cognitive Function and Ageing Studies (CFAS I and II) are large population-based studies of
those 65 years, conducted in three areas in England. Baseline occurred in 1991 (CFAS I, n=7635) and 2011
(CFAS II, n=7762) with two-year follow-up. We defined disability as difficulty in activities of daily living,
MLTCs as the presence of at least two of nine health conditions, and socioeconomic deprivation by area-level
deprivation tertiles. DFLE and transitions between disability states and death were estimated frommultistate
models.
Findings: : For people with MLTCs, inequalities in DFLE at age 65 between the most and least affluent widened
to around 2.5 years (men:2.4 years, 95% confidence interval (95%CI) 0.44.4; women:2.6 years, 95%CI
0.74.5) by 2011. Incident disability reduced for the most affluent women (Relative Risk Ratio (RRR):0.6,
95%CI 0.40.9), and mortality with disability reduced for least affluent men (RRR:0.6, 95%CI 0.50.8). MLTCs
prevalence increased only for least affluent men (1991: 58.8%, 2011: 66.9%) and women (1991: 60.9%, 2011:
69.1%). However, DFLE inequalities were as large in people without MLTCs (men:2.4 years, 95%CI 0.34.5;
women:3.1 years, 95% CI 0.85.4).
Interpretation: : Widening DFLE inequalities were not solely due to MLTCs. Reduced disability incidence with
MLTCs is possible but was only achieved in the most affluent.







Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
Inequalities in life expectancy (LE) at birth in the UK have
been widening for some time [1] and currently stand at ten years
for men and eight years for women [2], with important sex dif-
ferences. Before the recent COVID-19 pandemic, all men had seen
increases in LE at birth, but gains were greatest in the least
deprived. In contrast, for the most deprived women, LE fell by93.5 days between 20132015 and 20162018. Since the pan-
demic, LE at birth has fallen further, for women by 0.9 years, and
for men by 1.2 years [3] .Healthy life expectancy at birth, which
combines health and mortality in one measure, shows even
greater inequalities across socioeconomic groups, [2] being
18.3 years for males, and 18.8 years for females [2]. Previous
work with the Cognitive Function and Ageing Studies (CFAS) has
shown that, between 1991 and 2011, inequalities in disability-
free life expectancy (DFLE) at age 65 increased by 1.7 years for
men and 2.4 years for women. This resulted from improvements
in the incidence of and recovery from disability in the most afflu-
ent men and women [4].
Research in context
Evidence before this study
After searching multiple databases, one cross-sectional and six
longitudinal panel studies of moderate quality reported disabil-
ity-free life expectancy (DFLE) comparisons for multiple long-
term conditions (MLTCs) including diabetes, cardiovascular dis-
eases, depression and sensory impairment. Evidence was lim-
ited but suggests that LE and DFLE were generally reduced for
those with MLTCs, though the impact of MLTCs may not be
additive but dependent on the combination of conditions stud-
ied. We identified no studies examining the impact of MLTCs
on DFLE by socioeconomic groups.
Added value of this study
Our study is the first to investigate the contribution of MLTCs to
widening inequalities in DFLE by socioeconomic deprivation.
We found that the least affluent older people with MLTCs spent
a greater proportion of remaining life with disability in 2011
than 1991, providing some evidence that MLTCs may have
become more disabling in this group. However, although MLTCs
may be contributing to the widening LE and DFLE inequalities
seen in the UK, it is not the full story, as DFLE inequalities for
those without MLTCs were of a similar magnitude to those with
MLTCs.
Implications of all the available evidence
This study suggests that a reduction in disability incidence or a
delay in the onset of disability could occur, even in the presence
of MLTCs. However, to date, this has only been achieved for the
most affluent older women. These results, and the greater
impact of Covid-19 on disadvantaged communities, render it
unlikely that the Ageing Grand Challenge, of increasing healthy
life expectancy by five years before 2035 while also reducing
inequalities, will be met.
2 H.Q. Bennett et al. / EClinicalMedicine 39 (2021) 101041Widening inequalities in life expectancy at birth are due to higher
death rates from respiratory disease, ischaemic heart disease and
dementias in the least affluent [5]. Additionally, there is evidence
that inequalities in life expectancy at age 65 are a result of delayed
onset of multiple long-term conditions (MLTCs) of two years for men
and three for women, together with longer survival with MLTCs for
men of one year [6]. Recent evidence from Canada suggests that the
prevalence of MLTCs has increased by 12% over the last decade, even
after allowance for the increased ageing of the population. Earlier
detection, in particular with hypertension, diabetes and mild cogni-
tive impairment, may however also be a contributing factor [7].
There has been less research on the impact of MLTCs on DFLE. The
majority of studies investigate combinations of two conditions only,
or the presence of comorbidity with a specific condition. In these
studies, the presence of other conditions tended to reduce LE and
DFLE compared to having the health condition alone [8,9]. Only one
study to date has reported the effect of cumulative MLTCs on DFLE,
[10] and another has investigated the effect of combinations of condi-
tions on DFLE in different racial groups [11]. However, no-one has
researched whether MLTCs contribute to trends in socio-economic
inequalities in DFLE.
We aim to address these shortcomings and determine whether
widening DFLE inequalities between the most and least affluent older
men and women in the UK is because of a greater increase in the
prevalence of MLTCs in the least affluent or because MLTCs have
become less disabling for the most affluent.2. Methods
2.1. Data
The Cognitive Function and Ageing Studies (CFAS I and CFAS II) are
two large population based longitudinal studies of those aged 65 and
over conducted two decades apart. Both were based in the same
three areas of England  Cambridgeshire, Nottingham and Newcastle
upon Tyne. For each study a random sample from the Family Health
Service Authority lists were approached through letter jointly signed
by their general practitioner and local principal investigator. Sam-
pling was stratified into age groups 6574 and 75 and over and with
an identical sampling strategy in CFAS I and CFAS II. If the participant
agreed, they were asked to sign a consent form and a mutually conve-
nient time was agreed for the interviewer to visit them in their home,
where responses to the questionnaire were recorded digitally. Fig. 1
shows the numbers of individuals from ascertainment to participa-
tion in CFAS I and CFAS II, and has previously been published in
greater detail [12]. Baseline interviews began in 1991 for CFAS I, and
2008 for CFAS II, with follow up interviews conducted two years later.
Anyone who had participated at baseline and were still alive were re-
approached and anyone who did not refuse, move or get lost to fol-
low-up were re-interviewed. A subsample of participants nominated
a friend or family member for an informant interview, which we
used to substitute missing data in the participant interview. The
Office for National Statistics (ONS) supplied date of death routinely
and was available up to 4.5 years after baseline interviews. For fur-
ther detail please see the study protocol on the CFAS website [13,14].
2.2. Measures
The disability measure was based on the modified Townsend
activities of daily living scale [15,16]. Being unable to leave their
house or requiring help with washing all over, preparing and cooking
a hot meal, putting on shoes and socks, heavy housework or shopping
and carrying heavy bags would categorise an individual as having
disability. If no help was required and they were ambulant outside
their house then they would be disability-free. The Townsend depri-
vation index [17], a measure of material index based on locality data
applied to individuals based on their postcode, was used as a measure
of socioeconomic deprivation and split into tertiles for each study.
The multiple long-term conditions (MLTCs) measure comprised hav-
ing two or more of: arthritis, coronary heart disease (angina or heart
attack), diabetes, peripheral vascular disease, respiratory difficulties
(asthma or bronchitis), stroke, hearing difficulties, visual impairment,
or cognitive impairment. Cognitive impairment was determined
from a Mini Mental State Examination (MMSE) [18] score of 25 or
less. Hearing difficulties and visual impairment were a combination
of self-report and interviewer rating. The interviewer was asked
whether poor eyesight or hearing problems interfered with the inter-
view and could give one of the following options: no, to some extent,
to a marked extent or blind/deaf. All other health conditions were
self-report of a doctor diagnosis. If a participant was missing data on
any of the health conditions, they were considered to have MLTCs if
the percentage of the health conditions present was 22.2% (equiva-
lent to two or more out of nine health conditions). For example, if
information was only present on 6 of the health conditions for a par-
ticipant, this would not be included as having missing MLTCs as they
do not have a record of health conditions, instead if they had 2 out of
6 of the health conditions recorded (33.3% > 22.2%), they would be
recorded as having MLTCs.
2.3. Statistical methods
The prevalence of MLTCs was estimated at baseline and two year
follow up. Decline and recovery transitions between disability-free,
Fig. 1. Flow chart of individuals through the Cognitive Function and Ageing Studies (CFAS I and CFAS II) from ascertainment to inclusion in the study.
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model, and then combined to estimate life and health expectancies in
Interpolated Markov Chain software (IMaCh [19] version 0.99r19).
Fig. 2 describes the transitions being estimated by the multistate
model, including remaining in one of the alive states, transitioning to
disability (incident disability), recovery from disability to disability-
free and transitioning from either disability-free or with disability to
death. In IMaCh, time is modelled discretely in steps throughmultinomial logistic regression, with the steps starting at two years
and wherever possible gradually being decreased to one month to
become closer to continuous time, for more detail see appendix.
Models for LE and DFLE were stratified by study and sex, as LE and
DFLE differ greatly between studies and sexes, and adjusted for depri-
vation and MLTCs. Steps could be decreased to one month. These
models were also used to estimate state-based life and health expec-
tancies for those initially free of disability. To estimate the relative
Fig. 2. Transitions in the multistate models used to estimate disability-free life expectancy, years with disability and transition probabilities.
Table 1
Number and weighted percentage of men and women in each deprivation
group at baseline with multiple long term health conditions in the Cognitive
Function and Ageing Studies (CFAS I and II). Percentages inverse probability
weighted.
Sex Socioeconomic deprivation CFAS I CFAS II
n % n %
Men Most affluent 506 47.0 647 47.6
Moderately affluent 473 48.6 612 53.4
Least affluent 573 58.8 641 66.9
Women Most affluent 757 52.2 793 52.6
Moderately affluent 845 55.5 816 57.4
Least affluent 948 60.9 802 69.1
4 H.Q. Bennett et al. / EClinicalMedicine 39 (2021) 101041probability of transitioning between each state in CFAS II compared
to CFAS I, models were stratified by sex, deprivation and MLTCs, and
adjusted for study. The stratified groups did not have as large num-
bers and therefore steps could only be reduced to six months. Inverse
probability weights for longitudinal attrition including age, sex, study
centre, deprivation, MMSE, functional impairment, education level,
social class, grouped count of health conditions, self-reported health
and smoking status were multiplied by baseline weights that
included age, sex, centre and deprivation to ensure population repre-
sentativeness for each of the study samples. An additional weight
was created for those who died, taking into account the probability of
death at each year of age from national mortality data from ONS in
comparison to CFAS. To validate IMaCh, we compared the estimates
of LE at age 65 and 85 for men and women in CFAS I and CFAS II from
IMaCh to LE estimates for England from the Office for National Statis-
tics and found them to be close (Appendix Table 1).
2.4. Role of the funding source
The funding source had no role in the study design, data collec-
tion, data analysis, data interpretation, writing of the report or deci-
sion to submit the paper for publication. All authors confirm they had
full access to the data in the study and accept responsibility for the
decision to submit for publication.
2.5. Ethics
The current ethics for MRC CFAS is from Eastern MREC, reference
number 05/MRE05/37 and for the mortality data Wales REC 7, refer-
ence number 14/WA/1154. The current REC reference number for
CFAS II is 07/MRE05/48 from Cambridge REC 4. For further informa-




The average age of the 7635 participants at baseline in CFAS I
(1991) was 75.6 years and 60.8% were women. Two years later, 5156
were re-interviewed, 76% of the 6816 still alive. Out of the 7762 par-
ticipants at baseline in CFAS II (2011), 56.1% were women and aver-
age age was 76.4 years. There were 5288 returning participants for
the two-year follow-up interview, 74% of the 7119 still alive. Total
follow-up was 28930.4 years in CFAS I, on average 4.5 years and forCFAS II total follow-up was 30027.8 years, 4.7 years on average. In
CFAS I 31.5% had disability at baseline (missing 1.1%) and of those
who participated in two year follow-up, 37.4% had disability (missing
2.8%). At baseline in CFAS II 36.4% had disability (missing 4.0%) and at
the two year follow-up 36.6% of those who participated had disability
(missing 0.7%). Cut points for deprivation tertiles in CFAS I were -1.37
and 2.75, cut points for CFAS II were -2.07 and 1.11 with no missing
data in CFAS I or CFAS II. The crude prevalence of MLTCs at baseline
was ten percentage points higher in the least affluent men in 1991
(least affluent: 58.8%, most affluent: 47.0%), and almost 20 percentage
points higher in 2011 (least affluent: 66.9%, most affluent: 47.6%),
with a similar pattern in women (Table 1). The crude prevalence of
MLTCs in the most affluent men and women changed little between
1991 and 2011 but increased for the least affluent (Table 1). Missing
data for MLTCs was 0.1% in CFAS I and 0.4% in CFAS II. Further demo-
graphic information is provided in other CFAS papers [13,20].
3.2. Life expectancies and disability-free life expectancies at age 65
In the presence of MLTCs, increases in disability-free years
between 1991 and 2011 were greater for the most affluent men
whereas increases in years with disability were greater for the least
affluent men (Fig. 3). Therefore, by 2011, although the percentage of
life spent with disability was still greater for men with MLTCs, it was
no longer similar across deprivation groups, with the least affluent
men spending almost a third of their remaining life with disability
(Table 2). In 1991, MLTCs were associated with increased risk of inci-
dent disability and increased risk of death with disability in men
(Table 3). By 2011 MLTCs were again associated with increased risk
of incident disability and men in the less affluent group were less
likely to recover from disability (Table 3).
Fig. 3. Gain (+) and loss (-) in disability-free life expectancy (DFLE) and years with disability (DLE) between the Cognitive Function and Ageing Studies (CFAS I and CFAS II).
Table 2
Life expectancy (LE), disability-free life expectancy (DFLE) and life expectancy with disability (DLE) at age 65 by sex, socio-economic deprivation and with 0-1 health condi-
tions or 2+ health conditions in the Cognitive Function and Ageing Studies (CFAS I and II). Difference between most and least affluent in each category.
Sex Socioeconomic deprivation CFAS I CFAS II
01 health conditions 2+ health conditions 01 health conditions 2+ health conditions
Years % Years % Years % Years %
Men Most affluent LE 16.6 (15.417.7) 12.5 (11.513.4) 20.6 (19.221.9) 17.0 (15.818.3)
DFLE 12.8 (11.614.1) 77.3 8.8 (7.79.9) 70.7 17.4 (15.918.8) 84.5 12.7 (11.314.1) 74.9
DLE 3.8 (3.04.5) 22.7 3.7 (3.04.3) 29.3 3.2 (2.44.0) 15.5 4.3 (3.55.0) 25.1
Moderately affluent LE 16.5 (15.217.8) 12.4 (11.313.5) 20.2 (18.821.6) 16.4 (15.317.6)
DFLE 12.9 (11.514.3) 78.2 8.9 (7.610.1) 71.4 16.6 (15.118.2) 82.3 11.8 (10.413.2) 71.8
DLE 3.6 (2.84.4) 21.8 3.5 (2.94.2) 28.6 3.6 (2.74.4) 17.7 4.6 (3.95.4) 28.2
Least affluent LE 15.9 (14.517.2) 11.7 (10.712.8) 18.7 (17.220.1) 15.3 (14.216.4)
DFLE 12.1 (10.613.5) 76.0 8.1 (6.99.3) 68.9 14.9 (13.416.5) 80.0 10.4 (9.011.7) 67.8
DLE 3.8 (2.94.7) 24.0 3.6 (3.04.3) 31.1 3.7 (2.84.7) 20.0 4.9 (4.15.8) 32.2
Difference most-least affluent LE 0.7 (-1.12.5) 0.7 (-0.72.2) 1.9 (-0.13.9) 1.7 (0.13.4)
DFLE 0.8 (-1.22.7) 0.7 (-0.92.4) 2.4 (0.34.5) 2.4 (0.44.3)
DLE 0.05 (1.21.1) 0.01 (0.90.9) 0.5 (1.80.7) 0.6 (1.80.5)
Women Most affluent LE 19.9 (18.821.1) 17.3 (16.418.2) 24.4 (22.826.0) 19.8 (18.621.0)
DFLE 12.0 (10.913.1) 60.2 8.4 (7.49.4) 48.6 16.4 (14.718.1) 67.2 10.7 (9.312.2) 54.2
DLE 7.9 (7.08.9) 39.8 8.9 (8.09.7) 51.4 8.0 (6.79.3) 32.8 9.1 (7.910.3) 45.9
Moderately affluent LE 19.1 (17.820.5) 16.8 (15.618.0) 23.1 (21.524.7) 19.0 (17.620.3)
DFLE 11.4 (10.112.6) 59.5 8.0 (6.99.1) 47.5 15.7 (14.017.3) 67.9 10.4 (8.911.8) 54.7
DLE 7.7 (6.68.9) 40.5 8.8 (7.79.9) 52.5 7.4 (6.28.7) 32.1 8.6 (7.49.8) 45.3
Least affluent LE 18.2 (16.819.6) 15.9 (14.717.1) 21.9 (20.2  23.6) 17.7 (16.618.8)
DFLE 11.2 (9.912.4) 61.4 7.9 (6.88.9) 49.5 13.3 (11.714.9) 60.7 8.1 (6.99.4) 45.9
DLE 7.0 (5.98.1) 38.6 8.0 (7.09.0) 50.5 8.6 (7.210.0) 39.3 9.6 (8.410.8) 54.2
Difference most-least affluent LE 1.8 (0.13.6) 1.4 (0.12.9) 2.5 (0.24.8) 2.1 (0.43.7)
DFLE 0.8 (0.82.5) 0.5 (0.91.9) 3.1 (0.85.4) 2.6 (0.74.5)
DLE 0.9 (0.52.4) 0.9 (0.52.2) 0.6 (2.51.3) 0.5 (2.21.2)
H.Q. Bennett et al. / EClinicalMedicine 39 (2021) 101041 5The overall pattern of higher LE and DFLE in the most affluent
women with MLTCs was evident in 1991 and 2011, but was more
pronounced in 2011 (Table 2, Fig. 3). There is therefore someevidence that the most affluent men and the most and moderately
affluent women with MLTCs spent a lower proportion of remaining
life with disability in 2011 than 1991 (Table 2). For women, MLTCs
Table 3
Relative risk ratio (RRR) and 95% confidence intervals (CI) of transitioning between
disability states and death for men from different socioeconomic deprivation groups
and with and without multiple long-term conditions (MLTCs) adjusted as covariates,
and stratified by study (Cognitive Function and Ageing Studies CFAS I and CFAS II).
CFAS I CFAS II
Transition Covariate RRR 95% CI RRR 95% CI
No disability ->
Disability
Most affluent Ref. Ref.
Moderately affluent 1.1 (0.91.5) 1.1 (0.81.5)




2+ health conditions 1.8 (1.42.3) 2.2 (1.63.0)
No disability ->
Death
Most affluent Ref. Ref.
Moderately affluent 1.0 (0.71.5) 0.9 (0.51.6)




2+ health conditions 1.3 (0.91.9) 1.1 (0.71.7)
Disability -> No
disability
Most affluent Ref. Ref.
Moderately affluent 1.5 (0.92.4) 0.8 (0.51.3)




2+ health conditions 0.7 (0.41.3) 0.9 (0.61.3)
Disability -> Death Most affluent Ref. Ref.
Moderately affluent 1.0 (0.81.2) 1.0 (0.81.3)




2+ health conditions 1.4 (1.11.7) 1.1 (0.91.4)
Table 4
Relative risk ratio (RRR) and 95% confidence intervals (CI) of transitioning between
disability states and death for women from different socioeconomic deprivation
groups and with and without multiple long-term conditions (MLTCs), adjusted as
covariates, and stratified by study (Cognitive Function and Ageing Studies CFAS I and
CFAS II).
CFAS I CFAS II
Transition Covariate RRR 95% CI RRR 95% CI
No disability ->
Disability
Most affluent Ref. Ref.
Moderately affluent 1.0 (0.81.2) 1.0 (0.81.3)




2+ health conditions 1.7 (1.42.0) 1.7 (1.32.1)
No disability ->
Death
Most affluent Ref. Ref.
Moderately affluent 1.5 (0.83.2) 1.6 (0.73.6)




2+ health conditions 1.0 (0.51.9) 1.0 (0.42.3)
Disability -> No
disability
Most affluent Ref. Ref.
Moderately affluent 0.9 (0.61.3) 1.0 (0.71.5)




2+ health conditions 0.7 (0.51.1) 0.6 (0.40.8)
Disability -> Death Most affluent Ref. Ref.
Moderately affluent 1.0 (0.91.1) 1.0 (0.91.2)




2+ health conditions 1.1 (0.91.3) 1.4 (1.11.7)
6 H.Q. Bennett et al. / EClinicalMedicine 39 (2021) 101041were associated with increased risk of incident disability in 1991 and
2011 (Table 4). For women in 2011, having MLTCs was also associated
with being less likely to recover from disability and being more likely
to die with disability; being less affluent was associated with
increased risk of incident disability (Table 4).
If the widening inequalities in DFLE between the most and least
affluent were a result of MLTCs then we would expect smaller DFLE
inequalities in older people without MLTCs. However, although there
was no evidence of differences between 1991 and 2011 in inequal-
ities in years with disability between the most and least affluent,
there were increases in inequalities in years disability-free for both
men and women without MLTCs. Indeed, the patterning across depri-
vation groups, and the magnitude of the inequalities in LE and DFLE
were similar between those without and with MLTCs (Table 2, Fig. 3).
Thus the widening inequalities in DFLE at age 65 over time previously
found [4] were not wholly due to the increased prevalence of MLTCs
since inequalities in DFLE between the most and least affluent also
widened in those without MLTCs.
We conducted further analyses to ascertain whether the widening
DFLE inequalities in individuals without MLTCs resulted from the
least affluent having either a greater prevalence of disability at base-
line, or a greater incidence of MLTCs in the two-year follow-up, with
therefore a subsequent faster onset of disability. Firstly, we examined
the change in inequalities by social deprivation between 1991 and
2011 in those who were initially disability-free at baseline through
status-based life tables. In 1991, inequalities in DFLE at age 65
between the most and least affluent who were initially disability-free
and without MLTCs were small (men: 0.7 years, 95% confidence inter-
val (CI) -1.0 to 2.4; women: 0.9 years, 95% CI -0.6 to 2.4) (Fig. 4,
Table 5). By 2011, these inequalities had more than tripled (men:
2.2 years, 95% CI 0.2 to 4.2; women: 3.0 years, 95% CI 0.8 to 5.2)
(Fig. 4, Table 5). Secondly, we explored whether the percentage of
individuals initially free of MLTCs who acquired them by the two-
year follow-up increased between 1991 and 2011, and whether these
changes were different between the most and least affluent. In 2011,a slightly smaller percentage of men and women acquired MLTCs
during follow-up, compared to 1991, with the least affluent men and
the most affluent women showing the greatest reductions (Table 6).
Thus, there is little evidence that the widening inequalities in DFLE
between the most and least affluent without MLTCs were due to a
greater prevalence of disability at baseline in the least affluent, or a
differential incidence of MLTCs from baseline to follow-up between
deprivation groups.
Finally, we investigated which underlying transitions (incidence
of, and recovery from, disability, and mortality) were contributing to
the increase in inequalities in DFLE over time in those with and with-
out MLTCs. For men with MLTCs, the wider DFLE inequalities by 2011
stemmed from reductions in the risk of death from a disability-free
state in the most affluent men, and reductions in the risk of death
with disability for the least affluent men (Table 7), resulting in the
most affluent men living longer disability-free but the least affluent
living longer with disability. The greater inequalities in women with
MLTCs in 2011 compared to 1991 stemmed from the most and mod-
erately affluent women having a lower incidence of disability in 2011
than 1991 (Table 7). For those without MLTCs, the most affluent saw
both reductions in the incidence of disability between 1991 and 2011
(men and women), and in the risk of death from disability-free
(men), or from disability (women) (Table 7). In contrast, the least
affluent men and women without MLTCs saw little change in any
transitions, with only a decrease in incident disability for men.
Women in the middle deprivation group without MLTCs had evi-
dence of improvements in the risk of recovery from disability,
explaining the smaller increases in DLE between 1991 and 2011 com-
pared to the most affluent (Table 7).
4. Discussion
Widening inequalities in LE by social deprivation have been
reported [5]. Although the contribution of MLTCs to shorter life and
Fig. 4. Gain (+) and loss (-) in disability-free life expectancy (DFLE) and years with disability (DLE) between the two Cognitive Function and Ageing Studies (CFAS I and CFAS II) for
those disability-free at baseline.
Table 5
Life expectancy (LE), disability-free life expectancy (DFLE) and life expectancy with disability (DLE) at age 65 for those disability-free at baseline by sex, socio-economic dep-
rivation and with 01 health conditions or 2+ health conditions in the Cognitive Function and Ageing Studies (CFAS I and II). Difference between most and least affluent in
each category.
Sex Socioeconomic deprivation CFAS I CFAS II
01 health conditions 2+ health conditions 01 health conditions 2+ health conditions
Years % Years % Years % Years %
Men Most affluent LE 16.9 (15.818.0) 13.0 (12.113.9) 20.7 (19.422.0) 17.3 (16.218.4)
DFLE 13.3 (12.214.4) 78.6 9.6 (8.610.5) 73.6 17.6 (16.219.0) 85.0 13.2 (12.014.4) 76.2
DLE 3.6 (2.94.3) 21.4 3.4 (2.94.0) 26.4 3.1 (2.33.9) 15.0 4.1 (3.44.9) 23.8
Moderately affluent LE 16.7 (15.418.0) 12.8 (11.713.8) 20.4 (19.021.8) 16.8 (15.817.9)
DFLE 13.2 (12.014.5) 79.1 9.4 (8.410.5) 73.7 16.9 (15.518.4) 83.0 12.4 (11.213.6) 73.5
DLE 3.5 (2.74.3) 20.9 3.4 (2.74.0) 26.3 3.5 (2.74.3) 17.0 4.5 (3.75.2) 26.5
Least affluent LE 16.2 (14.917.5) 12.3 (11.313.3) 18.9 (17.520.4) 15.8 (14.816.8)
DFLE 12.5 (11.213.8) 77.4 8.9 (7.99.9) 72.2 15.4 (13.916.8) 81.1 11.2 (10.012.3) 70.7
DLE 3.7 (2.84.5) 22.6 3.4 (2.84.0) 27.8 3.6 (2.74.5) 18.9 4.6 (3.95.4) 29.3
Difference most-least affluent LE 0.7 (1.02.4) 0.7 (0.72.0) 1.8 (0.23.7) 1.5 (0.013.0)
DFLE 0.7 (1.02.4) 0.7 (0.72.0) 2.2 (0.24.2) 2.0 (0.43.7)
DLE 0.05 (1.11.0) 0.0 (0.80.8) 0.5 (1.60.7) 0.5 (1.60.6)
Women Most affluent LE 20.1 (18.921.2) 17.6 (16.718.5) 24.4 (22.926.0) 20.0 (18.821.3)
DFLE 12.4 (11.413.3) 61.5 9.1 (8.39.9) 51.6 16.6 (15.018.2) 67.9 11.4 (10.212.7) 57.0
DLE 7.7 (6.88.7) 38.5 8.5 (7.79.3) 48.4 7.8 (6.69.1) 32.1 8.6 (7.59.7) 43.0
Moderately affluent LE 19.2 (17.920.6) 17.0 (15.818.2) 23.1 (21.524.8) 19.2 (17.820.6)
DFLE 11.7 (10.612.8) 61.0 8.7 (7.89.6) 51.0 15.9 (14.317.5) 68.7 11.1 (9.812.4) 57.7
DLE 7.5 (6.48.6) 39.0 8.4 (7.39.4) 49.0 7.2 (6.08.4) 31.3 8.1 (7.09.2) 42.3
Least affluent LE 18.3 (16.919.7) 16.1 (14.917.3) 22.0 (20.323.7) 18.0 (16.819.2)
DFLE 11.5 (10.412.6) 62.8 8.5 (7.69.4) 52.6 13.6 (12.115.1) 62.0 9.0 (7.910.1) 50.1
DLE 6.8 (5.87.8) 37.2 7.6 (6.78.6) 47.4 8.4 (7.09.7) 38.0 9.0 (7.910.1) 49.9
Difference most-least affluent LE 1.8 (0.033.6) 1.5 (0.13.0) 2.5 (0.14.8) 2.0 (0.43.7)
DFLE 0.9 (0.62.4) 0.6 (0.61.8) 3.0 (0.85.2) 2.4 (0.84.1)
DLE 0.9 (0.52.3) 0.9 (0.42.1) 0.5 (2.31.3) 0.4 (1.91.2)
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parisons have been made. Here we used two longitudinal popula-
tion-based studies of people aged 65 years and over in England toconsider the contribution of MLTCs to the previously reported widen-
ing inequalities in LE and DFLE by socioeconomic deprivation
between 1991 and 2011 of 1.7 years for men and 2.4 years for women
Table 6
Number and weighted percentage of men and women in each depri-
vation group who did not have multiple long-term conditions
(MLTCs) at baseline but developed them by two year follow-up in the
Cognitive Function and Ageing Studies (CFAS I and II). Percentages
longitudinally weighted.
CFAS I CFAS II
n % n %
Men Most affluent 84 19.1 93 16.9
Moderately affluent 95 24.7 88 21.3
Least affluent 83 28.2 53 22.9
Women Most affluent 124 23.2 98 17.4
Moderately affluent 141 27.8 106 22.9
Least affluent 142 33.3 74 30.4
8 H.Q. Bennett et al. / EClinicalMedicine 39 (2021) 101041[4]. We show that these widening DFLE inequalities between the
most and least affluent men and women were not due solely to the
increasing prevalence of MLTCs in the least affluent, since DFLE
inequalities increased in those without MLTCs (to 1.8 years for men
and 2.5 years for women). Widening DFLE inequalities were also evi-
dent in those initially disability-free, suggesting that higher disability
prevalence in the least affluent was also not a major contributor.
Moreover, there was little evidence of an increased incidence of
MLTCs in the least affluent men and women, compared to the most
affluent, between 1991 and 2011, which may also have explained the
widening DFLE inequalities by social deprivation. There was, how-
ever, some evidence for a reduction in the disabling consequences of
MLTCs in 2011 compared to 1991 in the most affluent, with small
reductions in the proportion of remaining life with disability, in con-
trast to an increase for the least affluent. We conclude therefore that,
whilst MLTCs are potentially part of the reason for widening inequal-
ities in DFLE, they are not the major contributor, since DFLE inequal-
ities of a similar magnitude are evident in older men and women
without MLTCs.
In contrast to other studies, we also explored which underlying
transitions in DFLE contributed to the widening inequalities between
the most and least affluent older people. We found sex differences in
those with and without MLTCs as we had found overall, [4] with the
most affluent men seeing a lower risk of death from a disability-free
state in 2011 than 1991 but the least affluent seeing a lower risk of
death from disability (resulting in an increase in years with disabil-
ity). The most affluent women in contrast saw reductions in the inci-
dence of disability between 1991 and 2011, irrespective of MLTCs.
CFAS I and CFAS II are large studies, representative of the UK pop-
ulation aged 65 years or over. They offer a rare opportunity for esti-
mating accurate time trends as the areas in which they wereTable 7
Relative Risk Ratio (RRR) of transitioning between disability states in the second Cognitive F
and number of multiple long-term conditions (MLTC), 95% confidence interval (CI) in pare
months (see methods).
Sex Multiple Long Term Conditions Socioeconomic deprivation No disability t
Men 0-1 health conditions Most affluent 0.6 (0.41.0)
Moderately affluent 0.7 (0.41.1)
Least affluent 0.5 (0.30.9)
2+ health conditions Most affluent 1.0 (0.71.5)
Moderately affluent 0.7 (0.41.0)
Least affluent 0.8 (0.51.2)
Women 0-1 health conditions Most affluent 0.7 (0.51.0)
Moderately affluent 0.7 (0.51.1)
Least affluent 0.8 (0.51.2)
2+ health conditions Most affluent 0.6 (0.40.9)
Moderately affluent 0.6 (0.40.8)
Least affluent 1.0 (0.71.4)conducted, their sampling strategy, approach of participants and
recruitment were identical. Both studies included people living in
care settings and assisted living facilities, important since the per-
centage of people with MLTCs has grown more in these places of resi-
dence than for those living in the community [20]. We included more
health conditions in the MLTCs measure than in other studies, mak-
ing it less likely the comparison group without MLTCs had health
conditions that were not recorded. There were, however, some limi-
tations related to ascertainment and analysis of MLTCs, the measure
of socioeconomic status, the CFAS I and II response rates and number
of follow-up interviews, and validation of the estimates of LE and
DFLE from IMaCh. Firstly, the majority of the health conditions were
self-reported, albeit of a previous doctor diagnosis, rather than from
medical records, although vision and hearing problems also included
interviewer observation. Although self-report of health conditions is
dependent on the participant’s memory, information from informant
interviews conducted with a friend or family member could replace
information on missing health conditions (and other variables).
Although medical records may not be biased by the participant’s
memory, other biases can occur, for instance lower attendance by
those in lower socioeconomic deprivation groups. We acknowledge
that the MLTCs measure was simplistic as a binary measure (0-1 ver-
sus 2 or more health conditions), instead of considering either clus-
ters of diseases or MLTCs as a count. However, as LE and DFLE
estimates were stratified by deprivation as well as MLTCs this choice
was necessary due to the number of transitions in each group, as
more MLTCs categories would have resulted in too low numbers for
convergence. Secondly, although we chose area deprivation as our
measure of socioeconomic deprivation to be more indicative of a par-
ticipant’s current rather than previous status (such as education or
occupation), it is an area level rather than individual level measure
based on possessions or pension income. Thirdly, in terms of the sam-
ples themselves, the CFAS II participation rate for the baseline inter-
view was lower than that for CFAS I. Nevertheless, factors associated
with non-response remained similar [12] and inverse probability
weights were used to ensure population representativeness at each
time point. In addition, the studies were based almost entirely on
areas with high white British populations and therefore cannot rep-
resent the British Black and Minority Ethnic (BAME) community, for
which dedicated studies are required to address this knowledge gap.
Race could not be included in the inverse probability weights as we
do not have this information for people who did not participate in
the studies. CFAS I has further follow-up interviews after two years,
however, CFAS II only has a follow-up interview at two. To replicate
the analysis in CFAS I and II, follow up had to be restricted in CFAS I
to only two years of interviews with 4.5 years of follow-up for vitalunction and Ageing Study (CFAS II) compared to CFAS I, by socioeconomic deprivation
nthesis. Models stratified by sex, SES and MLTCs with study as a covariate. Step m = 6
RRR (95% CI)
o disability No disability to death Disability to no disability Disability to death
0.5 (0.30.8) 2.1 (0.76.4) 1.3 (0.82.1)
0.6 (0.41.1) 1.0 (0.42.5) 0.9 (0.51.6)
0.7 (0.41.4) 0.6 (0.22.1) 0.7 (0.41.3)
0.5 (0.30.8) 1.7 (0.83.4) 0.9 (0.71.2)
0.4 (0.20.8) 1.0 (0.52.0) 0.8 (0.61.0)
1.1 (0.52.3) 1.1 (0.52.2) 0.7 (0.50.9)
0.6 (0.31.6) 1.0 (0.51.9) 0.5 (0.30.8)
0.8 (0.41.3) 3.5 (1.58.2) 0.7 (0.51.1)
0.4 (0.11.1) 1.1 (0.62.4) 1.1 (0.71.6)
0.8 (0.31.8) 0.7 (0.41.3) 1.1 (0.91.3)
0.4 (0.11.3) 1.1 (0.62.0) 1.0 (0.81.2)
0.5 (0.21.8) 1.2 (0.72.0) 0.8 (0.71.0)
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and 85 from our analysis using IMaCh were close to those published
for England by the Office for National Statistics, we could not validate
our estimates of DFLE as the Office for National Statistics use cross-
sectional methods and a different measure of disability. Furthermore,
we could not compare our estimates from discrete time models with
those from continuous time models since the software for the latter
[21] cannot accommodate weights which were necessary due to the
design of CFAS.
We broaden the scope of previous literature by reporting the dif-
ferential impact of MLTCs on inequalities in DFLE by socioeconomic
deprivation. Although we did not look at the addition of each health
condition individually, when comparing those with MLTCs to those
without, we found that both LE and DFLE are reduced for those with
MLTCs, similar to previous research [8,9,11], and to a similar degree
across all deprivation groups. The latter is in contrast to differences
by race [11] where MLTCs reduced LE more for white Americans than
African Americans, and yet the resulting increase in percentage of life
spent with disability was greater for African Americans than for
white Americans, particularly for men. However, small group num-
bers may mean that differences between groups are imprecise.
Our study is the first to our knowledge to investigate the contribu-
tion of MLTCs to trends in LE and DFLE between deprivation groups.
We found that, although the prevalence of MLTCs only increased for
the least affluent, this was not the sole reason for widening DFLE
inequalities by social deprivation, since widening DFLE inequalities
were also present in those without MLTCs. Inequalities in LE and
DFLE in those without MLTCs could be due to the causes of the causes
such as physical activity, smoking, alcohol consumption and diet. As
well as these behavioural factors contributing to the development of
MLTCs [6,22,23], they have direct associations with disability [24].
However, there is disagreement on whether behavioural factors
equally reduce LE [6,23], DFLE [23], and healthy life expectancy [6]
across all socioeconomic groups or differentially across socioeco-
nomic groups [22,25]. Between the generations included in CFAS I
and CFAS II there were some improvements to early life factors, such
as increases in the compulsory school leaving age in England. How-
ever, baseline CFAS II interviews began in 2008 so the full impact of
austerity measures on health, which unequally impacted the more
vulnerable [26,27], would not be measured between these two time
points. With this in mind, to prevent inequalities widening further, a
life-course perspective on the wider social determinants of health
has been suggested [1,28,29]. Recommendations include restoring
secondary school funding per pupil to previous levels, creating fair
employment opportunities through increasing the national living
wage and supporting in work training [1]. Built environment is asso-
ciated with cognitive impairment [30,31] and disability [32,33]. In
order to also ensure safe and healthy living environments, invest-
ment needs to be focussed on more deprived communities [1]. Pro-
viding access to more natural environments [31] and better
infrastructure [34] could result in improvements to health and well-
being.
Recently, the UK Government stated its aim to increase healthy
life expectancy by five years before 2035 while also reducing inequal-
ities [35]. The realisation of this aim may be substantially delayed
since COVID-19 has disproportionately affected the health and mor-
tality of the least affluent [36], in part thought to be due to the differ-
ence in prevalence of comorbid health conditions [37,38]. Individuals
with MLTCs have complex health care needs. In health care systems
based on specialisation in the treatment and care of people with sin-
gle health conditions, as in the case of primary care in the UK, this
will disproportionately impact more deprived groups where preva-
lence of MLTCs is rising. Providing support for health care professio-
nals, especially in primary care where time is limited, both in terms
of systems which encourage a multiple, rather than single, conditions
management approach [39], and also access to additional clinicalexpertise and treatments to reduce unnecessary polypharmacy and
increase patient safety, is urgently needed [22,40,41]. Social prescrib-
ing, where a link worker based in primary care supports people with
MLTCs to co-produce a personalised social prescription to address
behavioural change, is a promising intervention to improve wellbeing
and low mood [42], especially in more deprived communities [43].
Social prescribing may be a welcome change to taking multiple pre-
scription drugs for different health conditions. For maximum impact
both downstream (within health care systems) and upstream solu-
tions, such as unpolluted outdoor spaces, greater well-paid employ-
ment opportunities with safe working conditions and access to high
quality neighbourhood services such as housing, public transport and
schools, should be considered to delay the onset of long-term condi-
tions and reduce MLTCs in more deprived communities.
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